Harith Rajagopalan Sells 90,972 Shares of Fractyl Health, Inc. (NASDAQ:GUTS) Stock

Fractyl Health, Inc. (NASDAQ:GUTS) CEO Harith Rajagopalan sold 90,972 shares of the stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $1.82, for a total value of $165,569.04. Following the completion of the transaction, the chief executive officer now directly owns 491,329 shares of the company’s stock, valued at $894,218.78. This trade represents a 15.62 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Harith Rajagopalan also recently made the following trade(s):

• On Monday, November 11th, Harith Rajagopalan sold 96,517 shares of Fractyl Health stock. The shares were sold at an average price of $2.47, for a total value of $238,396.99.

Fractyl Health Trading Down 7.6 %

GUTS traded down $0.14 during trading on Monday, reaching $1.70. 583,333 shares of the company’s stock were exchanged, compared to its average volume of 409,278. The company’s fifty day moving average price is $2.06 and its 200-day moving average price is $2.51. The firm has a market capitalization of $81.77 million and a PE ratio of -0.14. Fractyl Health, Inc. has a fifty-two week low of $1.68 and a fifty-two week high of $13.99. The company has a debt-to-equity ratio of 0.60, a quick ratio of 5.57 and a current ratio of 5.58.

Fractyl Health (NASDAQ:GUTS) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.48) EPS for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.02. The company had revenue of $0.01 million during the quarter. As a group, equities analysts forecast that Fractyl Health, Inc. will post -1.66 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley lowered their price objective on Fractyl Health from $18.00 to $10.00 and set an “overweight” rating on the stock in a report on Monday.

Institutional Trading of Fractyl Health

A number of hedge funds have recently modified their holdings of GUTS. Massachusetts Financial Services Co. MA grew its holdings in Fractyl Health by 4.9% during the third quarter. Massachusetts Financial Services Co. MA now owns 1,045,672 shares of the company’s stock valued at $2,646,000 after purchasing an additional 49,289 shares during the period. Geode Capital Management LLC boosted its position in shares of Fractyl Health by 166.5% during the third quarter. Geode Capital Management LLC now owns 501,476 shares of the company’s stock worth $1,269,000 after purchasing an additional 313,335 shares in the last quarter. State Street Corp grew its holdings in shares of Fractyl Health by 129.4% in the 3rd quarter. State Street Corp now owns 113,415 shares of the company’s stock valued at $287,000 after buying an additional 63,968 shares during the period. Charles Schwab Investment Management Inc. increased its position in shares of Fractyl Health by 56.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 80,664 shares of the company’s stock valued at $204,000 after buying an additional 29,262 shares in the last quarter. Finally, Barclays PLC lifted its holdings in Fractyl Health by 1,754.7% during the third quarter. Barclays PLC now owns 47,796 shares of the company’s stock worth $121,000 after acquiring an additional 45,219 shares in the last quarter.

Fractyl Health Company Profile

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.